Sonoma Pharmaceuticals, Inc.
SNOA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $5,604 | $4,015 | $3,754 | $3,564 |
| % Growth | 39.6% | 7% | 5.3% | – |
| Cost of Goods Sold | $3,484 | $2,551 | $2,226 | $2,294 |
| Gross Profit | $2,120 | $1,464 | $1,528 | $1,270 |
| % Margin | 37.8% | 36.5% | 40.7% | 35.6% |
| R&D Expenses | $575 | $594 | $411 | $427 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1,882 | $1,965 | $1,773 | $1,874 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2,457 | $2,559 | $2,184 | $2,301 |
| Operating Income | -$337 | -$1,095 | -$656 | -$1,031 |
| % Margin | -6% | -27.3% | -17.5% | -28.9% |
| Other Income/Exp. Net | -$394 | -$147 | $128 | $112 |
| Pre-Tax Income | -$731 | -$1,242 | -$528 | -$919 |
| Tax Expense | -$197 | -$1 | $248 | $9 |
| Net Income | -$534 | -$1,241 | -$776 | -$928 |
| % Margin | -9.5% | -30.9% | -20.7% | -26% |
| EPS | -0.32 | -0.76 | -0.63 | -0.63 |
| % Growth | 57.9% | -20.6% | 0% | – |
| EPS Diluted | -0.32 | -0.76 | -0.63 | -0.63 |
| Weighted Avg Shares Out | 1,646 | 1,641 | 1,241 | 1,464 |
| Weighted Avg Shares Out Dil | 1,646 | 1,641 | 1,241 | 1,464 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $36 | $36 | $31 | $33 |
| EBITDA | -$695 | -$1,059 | -$625 | -$998 |
| % Margin | -12.4% | -26.4% | -16.6% | -28% |